TABLE 3.
Risk factors for unfavorable response in 274 patients with MAC-LDa
| Characteristic | No. (%) of patients with: |
P value by univariate analysis | Multivariate analysis |
||
|---|---|---|---|---|---|
| Treatment success (n = 218) | Unfavorable response (n = 56) | Adjusted OR (95% CI) | P value | ||
| Male gender | 79 (36.2) | 33 (58.9) | 0.002 | 1.474 (0.557–3.901) | 0.434 |
| Smoking history, former or current | 57 (26.1) | 28 (50.0) | 0.001 | 1.577 (0.591–4.203) | 0.363 |
| History of TB treatment | 87 (39.9) | 31 (55.4) | 0.037 | 1.273 (0.664–2.442) | 0.467 |
| Comorbidity, malignancy | 34 (15.6) | 15 (26.8) | 0.051 | 2.172 (0.989–4.771) | 0.053 |
| Positive AFB smear at treatment initiation | 82 (37.6) | 36 (64.3) | <0.001 | 2.769 (1.420–5.399) | 0.003 |
| In vitro MICs of: | <0.001 | ||||
| <8 μg/ml for rifampin and/or ethambutol | 168 (77.1) | 29 (51.8) | 1 | ||
| ≥8 μg/ml for rifampin and ethambutol | 50 (22.9) | 27 (48.2) | 3.154 (1.641–6.063) | 0.001 | |
a
TB, tuberculosis; AFB, acid-fast bacilli; OR, odds ratio; CI, confidence interval.